Table 1.
Baseline clinical characteristics of 56 patients with HCC
| Clinical characteristics | Lenvatinib plus PD-1 inhibitors |
| Age, years | 54.5 (28–73) |
| ≥60 years | 17 (29.3) |
| Sex | |
| Male | 50 (89.3) |
| Female | 6 (10.7) |
| Eastern Cooperative Oncology Group performance status | |
| 0 | 52 (92.9) |
| 1 | 4 (7.1) |
| Child-Pugh score | |
| A | 55 (98.2) |
| B | 1 (1.8) |
| Barcelona Clinic Liver Cancer staging | |
| B | 2 (3.6) |
| C | 54 (96.4) |
| China Liver Cancer staging | |
| IIb | 2 (3.6) |
| IIIa | 38 (67.9) |
| IIIb | 16 (28.6) |
| Alpha-fetoprotein concentration ≥400 ng/mL* | 35 (62.5) |
| Presence of macrovascular invasion, extrahepatic metastasis, or both | 54 (96.4) |
| Macrovascular invasion | 53 (94.6) |
| Portal vein tumor thrombus | 47 (83.9) |
| Metastasis | 16 (28.6) |
| Lymph node | 13 (23.2) |
| Lung | 3 (5.4) |
| Hepatitis B virus infection† | 49 (87.5) |
| Hepatitis C virus infection‡ | 5 (8.9%) |
| Alcohol consumption§ | 22 (39.3) |
| Smoke status | 30 (53.6) |
| Prior local therapy for hepatocellular carcinoma | 3 (5.4) |
Data presented as median (minimum–maximum) or no. (%).
*There was one patient with missing alpha-fetoprotein concentration level (P045).
†Two patients with missing hepatitis B virus infection status (P003 and P045).
‡Three patients with missing hepatitis C virus infection status (P003, P033, and P039).
§One patient with missing alcohol consumption (P051).
¶Two patients with missing smoke status (P039 and P51).
HCC, hepatocellular carcinoma; PD-1, programmed cell death protein-1.